Fortis Healthcare Limited

rs 1

or presentation being issued in this regard is also enclosed. · The meeting commenced at 0900 Hours 1ST and concluded at /g 00 Hours 1ST. This is for your information and record. Thanking You For

rs,

ement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian

rs 1

THE QUARTER AND SIX · - - - .MONTHS EN_DED SEPTEMBER 30, 202_2 __ ~ /Ruoees in lacs\ Particulars 1. Revenue from operations 2. Other income 3. Total income (1 +2) ~ - 4. Expenses (a) Purcha

1 %

ue"), subject to approval of the shareholders and other regulatory approvals which constituted 31. 1 % share capital of the Company. The shareholders of the Company approved the Preferential Issue by r

0.77%

subsequent to which the shareholding of the erstwhile Promoter Group in the Company was reduced to 0.77%. In terms of agreements dated September 30, 2017, FHsL assigned the outstanding I CDs to a third p

71%

ubsidiary (i.e. Escorts Heart Institute and Research Centre Limited ("EHIRCL")), purchased further 71% equity interest in Fortis Healthstaff Limited("Healthstaff') at an aggregate consideration of Rupe

29%

while promoter group company. EHIRCL also could not directly takeover the loan, as EHIRCL (holding 29%) could not have taken over the burden of the entire debt of Healthstaff. Therefore, this transacti

71 %

lthstaff. Therefore, this transaction was in a way to help the erstwhile promoter group companies (71 % shareholders) to aVoid making payment for its share, and place EHIRCL in a situation where it woul

51 %

18, the Company through its subsidiary (i.e. Fortis Hospitals Limited ("FHsL")), purchased further 51 % equity interest in Fortis Emergency Services Limited (FESL) at an aggregate consideration of Rupee

49%

erstwhile promoter group company. FHsL also could not directly takeover the loan, as FHsL (holding 49%) could not have taken over the burden of the entire debt of FESL. Therefore, this transaction was

100%

ear 2014-15, the Company through its subsidiary (i.e. Fortis Hospitals Limited ("FHsL")), acquired 100% stake in Birdie & Birdie Realtors Pvt; Ltd. ("Birdie") from certain persons related to the erstwhil

14%

he erstwhile promoters, wherein Rupees 12,275 lacs were paid towards ICDs at a rate of interest of 14% per annum and Rupees 7,725 lacs were paid for the shares acquired. The total enterprise value of B

“In the aforesaid context, proper and sufficient care has also been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities on a going forward basis.”

“In the aforesaid context, proper and sufficient care has also been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities on a going forward basis.”

“Based on the external legal counsel advice, the Company believes that EHIRCL will be able to suitably defend the termination of lease deeds and allotment letters and accordingly considers that no adjustments are required to the unaudited Consolidated Financial Results.”

“By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

Fax

2

Adjustments for

2

Cash

2

Parent

1

Subsidiaries

1

Joint ventures

1

Associates

1

For further details please contact

1

Fax

Limited Review Report on unaudited standalone financial results of Fortis Healthcare Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 To the Board of Directors of Fortis Healthcare Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Healthcare Limited ("the Company") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement"). 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Compan

Adjustments for

Exceptional (Gain)/ Loss (net) Finance cost Interest income (Profit) / Loss on disposal of property, plant and equipment (net) Allowance for bad and doubtful trade receivables Allowance for bad and doubtful advances Depreciation and amortisation expense Provision / liability no longer required written back (Rupees in lacs) --· Standalone -·-·-- Unaudited Audited . ·- --- 42,481 45,624 130 2,124 90,359 10,026 787 34,870 6,563 2,472 2,282 1,995 58,552 48,992 141 1,805 1,09,490 5,681 1,112 26,550 6,036 2,650 2,289 1,957 58,995 46,275 1,49,354 1,55,765 10,43,594 . 10,42,621 (Rupees in lacs) Six Months ended September 30, 2022 September 30, 2021 Unaudited Unaudited 8,182 395 (3,888) 5,601 (8,426) 3 323 16 5,712 (4) 6,478 (6,614) 12 272 86 5,591 (64) FORTIS HEAL TH CARE LIMITED GIN: L85110PB1996PLC045933 Fortis Hospital, Sector 62 Phase -VIII, Mohali -160062 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2022 - - - - - - - - - - - - - P

Fax

+91 124 235 8613 Limited Review Report on unaudited consolidated financial results of Fortis Healthcare limited for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Fortis Healthcare Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financia I resu Its of Fortis Healthcare Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement''), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Secur

Subsidiaries

(i) Escorts Heart Institute and Research Centre Limited ("EHIRCL") (ii) Fortis Hospitals Limited (iii) Fortis Asia Healthcare Pte limited (iv) Fortis Healthcare International Limited (vi Fortis Global Healthcare (Mauritius) Limited (vi) Fortis Malar Hospitals Limited (vii) Malar Stars Medicare limited (viii) Fortis Health Staff limited 6 ~ R~ (o \;, r,:u111l·,sh,1> f,rm w11hN.ef,•~•r.,1,nn Nn 8!.612:?3) col'lvc•tech1110 r, '> a S (,, ur, I.> l,rn,1r~ tiall•lltvP<'•l"C'r•,h,i:, wdh llf>ll.~~•~lt"h('ln No ~AlHH911 w1rh e-Uec• horn o,10L,•1 1.1 201 '; :.311, Un<;r C 1:ntr.,I ~ \\'1111! .1,1d l~cuti ( \',1'111,;: f,t 1•,:o 11 P:uk .! N,•,< 11 C ~·llll'', ','.'•··,11,,nt,ru,•,,~,~hw~\· Go1cc.aC1.,,•:Ea-.fl. M...imb<>• 4(.ino,,J: BS R & Co. LLP (ix) Fortis Cancer Care Limited (x) Fortis La Femme Limited (xi) Fortis Health Management (East) Limited (xii) Hiranandani Healthcare Private Limited (xiii) SRL Limited (xiv) SRL Diagnostics Private Limited (xv) SRL Reach Limited (xvi) SRL Diagnostics

Joint ventures

(i) Fortis Cauvery (ii) Fortis C- Doc Healthcare Limited (iii) SRL Diagnostics (Nepal) Private Limited

Associates

(i) Lanka Hospitals Corporate Pie (ii) THR Infrastructure Pte Ltd {iii) RHT Health Trust ('RHT') 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We draw attention to the following Notes in the Statement: a. Note 7 and 8 of the Statement which deal with various matters including the ongoing investigation by Serious Fraud Investigation Office ("SFIO") on Fortis Healthcare Limited arid its subsidiaries regarding alleged improper transactions and non-compliances